ClinicalTrials.gg

Program

TMB-365

A development code. Also written as “TMB-365/TMB-380”.

Its studies are led by TaiMed Biologics.

Furthest: phase 2, since Mar 2, 20223 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TaiMed Biologics31 open or runningphase 2since Mar 2, 2022Jul 17, 2019May 2027phase 2 · NCT07215468

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 17, 2019First study: phase 1 study in HIV-1-infectionFirst studyNCT04027387 · 24 enrolled · United States, Puerto Rico
  2. Mar 2, 2022Phase 2 study in HIV-1-infectionNCT05275998 · 51 enrolled · United States
  3. Oct 9, 2025Phase 2 study in HIV -1 InfectionNCT07215468 · 88 enrolled · United States

Ahead

  1. May 2027Primary completion: phase 2 study in HIV -1 InfectionNCT07215468

TargetBeta

CD4 →read by rule
“TMB-365 is a monoclonal antibody that binds to the CD4 receptor.”study text, by rule · the study

Other programs on CD4

ProgramCompanyFurthest phaseStudies
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28
VRC07-523LSruleTaiMed Biologicsphase 23
Allogeneic BAFF-L-expressing CAR T Cells LMY-922ruleLuminary Therapeuticsphase 12

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07215468HIV -1 Infection · United States2Active, not recruitingMay 202788
NCT05275998HIV-1-infection · United States2CompletedNov 20, 202451
NCT04027387HIV-1-infection · United States, Puerto Rico1CompletedAug 18, 202124

How it is read

Names in the registry

  • “TMB-365”, 2 entries
  • “TMB-365/TMB-380”, 1 entry

Codes read as this program: TMB365.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.